Vascular Ulcers Treatment Market Analysis & Forecast: 2026-2033
The Vascular Ulcers Treatment market is anticipated to grow at a CAGR of 4.7% with USD 3.3 Bn in 2026 and is expected to reach USD 4.6 Bn in 2033. The emerging prevalence of diabetes (589 million), one of the main causes of vascular ulcers, is expected to bolster the growth of global vascular ulcers treatment market. Increasing number of clinical trials is expected to aid in the growth of the global vascular ulcers treatment market over the forecast period.
Venous ulcers drops is projected to account for the largest share of disease type in 2026, representing approximately 46% of the total volume. Owing to their remarkably high prevalence across the global population, well-established clinical management protocols, and the increasing burden of chronic venous insufficiency in aging demographics. The prevalence of CVD was 7.2%. The prominent forms of CVD were varicose veins (4.5%) as well as telangiectasias (2.1%).
Venous ulcers, also known as venous leg ulcers (VLUs), shows the most prevalent form of lower extremity ulceration globally, accounting for the majority of chronic wound cases managed in both outpatient and inpatient clinical settings.
The epidemiological burden of chronic venous insufficiency (CVI), a condition in which the venous valves of the lower extremities fail to function properly is growth inducing factor, leading to persistent venous hypertension, skin breakdown, and eventually ulcer formation.
Based on drug class, antibiotics dominates the market, accounting for a significant 30% share in 2026. Owing to the critical role they play in managing infections that are commonly associated with vascular ulcers, particularly venous leg ulcers, arterial ulcers, as well as diabetic foot ulcers. Diabetic foot ulcers are a common and severe complication of T2DM, affecting between 19% and 34% of individuals with diabetes during their lifetime.
Vascular ulcers are highly susceptible to bacterial colonization and subsequent infection due to impaired blood flow, compromised immune responses, as well as prolonged wound exposure to the external environment. According to the World Health Organization (WHO), chronic wounds including vascular ulcers is one of the most major healthcare burdens globally, as well as infection management remains the cornerstone of effective treatment protocols.
Antibiotics are routinely prescribed topically as well as systemically to combat polymicrobial infections that frequently involve organisms such as Staphylococcus aureus, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA).
To learn more about this report, Request Free Sample
Based on distribution channel, hospital dominate the market, accounting for a significant 50% share in 2026, owing to the complexity of vascular ulcer conditions that inherently demand specialized clinical environments, multidisciplinary care teams, and access to prescription-grade wound care therapeutics that are exclusively dispensed through institutionalized pharmaceutical settings. Globally, wound care expenditure reached a staggering USD 148.65 billion in 2022.
Vascular ulcers, encompassing venous leg ulcers, arterial ulcers, as well as mixed etiology ulcers, are chronic, recalibrating conditions that frequently require concurrent management of underlying comorbidities such as chronic venous insufficiency, peripheral arterial disease, and diabetes mellitus, all of which necessitate close physician supervision and hospital-grade pharmacological dispensing infrastructure.
According to the World Health Organization (WHO), chronic wounds including vascular ulcers disproportionately affect elderly populations and individuals with cardiovascular-related comorbidities, and the management of these conditions often requires structured inpatient or outpatient hospital-level engagement where hospital pharmacies serve as the central node of therapeutic supply chains.
Modern wound dressings are no longer just simple covers. They are now active healing materials that help control infection, manage wound fluid, and speed up healing. One important type is bioactive as well as antimicrobial dressings, especially those containing silver. These dressings slowly release silver ions, which kill bacteria including MRSA, Pseudomonas, etc., that are commonly found in vascular ulcers and other chronic wounds.
Clinical studies show that silver dressings can reduce bacteria in wounds by up to 30–45%, lower the need for antibiotics, and may shorten healing time by 2–4 weeks in some chronic wound cases. They are highly used in vascular ulcers as infection control is one of the biggest challenges in treatment.
|
Current Event |
Description and its Impact |
|
FDA approval and launch of next-generation antimicrobial wound dressings (e.g., nitric-oxide and silver-based dressings, 2025–2026) |
|
|
CMS reimbursement tightening and restructuring of wound care coverage (2025–2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America account 40% market share in 2026, owing to its widespread adoption of advanced wound care technologies, and a significantly high prevalence of chronic vascular conditions that directly contribute to the development of vascular ulcers. According to the American Academy of Home Care Medicine, approximately 6.5 million people, or about 1 in 38 adults, are affected by chronic wounds each year in the US.
The United States, in particular, stands as a dominant force within this segment, largely fueled by the burden of conditions including chronic venous insufficiency, peripheral arterial disease, diabetes-related vascular complications, etc.
According to the Centers for Disease Control and Prevention (CDC), approximately 37.3 million Americans are living with diabetes, a condition strongly associated with peripheral vascular disease as well as subsequent ulcer formation, which directly amplifies the demand for effective vascular ulcer treatment solutions.
Furthermore, the American Heart Association has consistently showed that venous leg ulcers affect nearly 1% of the adult population in the United States, with recurrence rates exceeding 70% in untreated or inadequately managed cases.
The Asia Pacific region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 8.2%. Driven by a rapidly expanding diabetic population, aging demographics, as well as accelerating improvements in healthcare access across emerging economies including China, India, Japan, South Korea, Southeast Asian nations, IDF projects that the number of people with diabetes in the SEA Region will increase by 73%, reaching 185 million by 2050.
The International Diabetes Federation has highlighted that Asia is home to the largest number of people living with diabetes globally, with China as well as India collectively accounting for an enormous proportion of global diabetes cases, both of which are primary risk factors for diabetic foot ulcers and peripheral arterial disease-related vascular wounds.
The World Health Organization has reported escalating trends of hypertension as well as cardiovascular disease across Asia Pacific nations, conditions that are closely related to the development of arterial ulcers. Governments across the region are responding proactively; for instance, Japan's Ministry of Health, Labour and Welfare has progressively updated its national health insurance coverage to include advanced wound care dressings and vascular intervention procedures.
The U.S. contributes the highest share in the market in North America owing to its well-established healthcare infrastructure, extensive reimbursement frameworks, and the disproportionately high prevalence of chronic conditions that directly predispose the population to vascular ulcers.
The United States remains the dominant subsegment within the North American vascular ulcers treatment landscape, driven by a convergence of epidemiological burden, healthcare expenditure patterns, and accelerated adoption of advanced wound care modalities. According to the Centers for Disease Control and Prevention (CDC), approximately 37.3 million Americans are living with diabetes, a condition closely associated with the development of diabetic foot ulcers as well as venous leg ulcers, creating an enormous patient pool requiring sustained wound management interventions.
Furthermore, the American Heart Association has consistently reported that peripheral artery disease (PAD), a leading driver of arterial ulcers, affects approximately 8.5 million Americans aged 40 and above, further reinforcing the country's dominant position in driving treatment demand.
China contributes the highest share in the vascular ulcers treatment market in Asia Pacific due to its extraordinarily escalating aging population base, which serves as the primary driver for the high prevalence of venous as well as arterial ulcers across the country.
According to the National Bureau of Statistics of China, by 2023, individuals aged 60 years and above accounted for approximately 21.1% of the total population, translating into nearly 297 million elderly citizens who are inherently more susceptible to chronic wound conditions including vascular ulcers.
China's robust healthcare infrastructure expansion under the national "Healthy China 2030" initiative has substantially increased access to advanced wound care treatment modalities, facilitating greater patient diagnosis and treatment uptake.
Some of the major key players in Vascular Ulcers Treatment market include, Bristol Myers Squibb Co., Sanofi, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Cadila Pharmaceuticals Ltd.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.3 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.7% | 2033 Value Projection: | USD 4.6 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Bristol Myers Squibb Co., Sanofi, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Cadila Pharmaceuticals Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
